These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
186 related items for PubMed ID: 1554974
1. Ocular carteolol. A review of its pharmacological properties, and therapeutic use in glaucoma and ocular hypertension. Chrisp P, Sorkin EM. Drugs Aging; 1992; 2(1):58-77. PubMed ID: 1554974 [Abstract] [Full Text] [Related]
2. Ocular carteolol: a review of its use in the management of glaucoma and ocular hypertension. Henness S, Swainston Harrison T, Keating GM. Drugs Aging; 2007; 24(6):509-28. PubMed ID: 17571916 [Abstract] [Full Text] [Related]
4. [Efficacy and safety of long-acting carteolol 1% once daily. A double-masked, randomized study]. Trinquand C, Romanet JP, Nordmann JP, Allaire C, Groupe d'étude. J Fr Ophtalmol; 2003 Feb; 26(2):131-6. PubMed ID: 12660585 [Abstract] [Full Text] [Related]
5. Efficacy of the combination of carteolol hydrochloride + latanoprost in the treatment of glaucoma and ocular hypertension. Soares RR, Razeghinejad MR. Expert Opin Pharmacother; 2018 Oct; 19(15):1731-1738. PubMed ID: 30295543 [Abstract] [Full Text] [Related]
6. [Tolerance and pharmacologic effectiveness of antiglaucoma eyedrops]. Flury H, Tournoux A, Martenet AC. Klin Monbl Augenheilkd; 1986 Jun; 188(6):573-5. PubMed ID: 3761959 [Abstract] [Full Text] [Related]
7. Topical ophthalmic beta-adrenergic blockade for the treatment of glaucoma and ocular hypertension. Frishman WH, Fuksbrumer MS, Tannenbaum M. J Clin Pharmacol; 1994 Aug; 34(8):795-803. PubMed ID: 7962666 [Abstract] [Full Text] [Related]
9. Latanoprost : an update of its use in glaucoma and ocular hypertension. Perry CM, McGavin JK, Culy CR, Ibbotson T. Drugs Aging; 2003 Aug; 20(8):597-630. PubMed ID: 12795627 [Abstract] [Full Text] [Related]
11. [Effect of 0.004% travoprost and 2% carteolol on intraocular pressure in patients with ocular hypertension after laser peripheral iridotomy or trabeculectomy in primary angle-closure glaucoma]. Yao BQ, Pang YY, Li YX. Zhonghua Yan Ke Za Zhi; 2013 Apr; 49(4):340-4. PubMed ID: 23900094 [Abstract] [Full Text] [Related]
13. [Aqueous humor flow measured by fluorophotometry. A comparative study of the effect of various beta-blocker eyedrops in patients with ocular hypertension]. Coulangeon LM, Sole M, Menerath JM, Sole P. Ophtalmologie; 1990 Apr; 4(2):156-61. PubMed ID: 2235007 [Abstract] [Full Text] [Related]
16. Dorzolamide. A review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension. Balfour JA, Wilde MI. Drugs Aging; 1997 May; 10(5):384-403. PubMed ID: 9143858 [Abstract] [Full Text] [Related]
17. [Carteolol: general practice-oriented assessment of the effectiveness and tolerance of a new beta-blocker in the treatment of glaucoma]. Schnaudigel OE, Becker H, Fuchs HB. Klin Monbl Augenheilkd; 1988 Mar; 192(3):248-51. PubMed ID: 3374015 [Abstract] [Full Text] [Related]
18. [Hypotensive action of 0.5% carteolol versus 0.1% timolol in patients with intraocular hypertension]. Allaire C, Trinquand C, Nordmann JP, Dascotte JC, George JL, Lesure P, Rouland JF, Khaitrine L, Sirbat D. J Fr Ophtalmol; 1995 Mar; 18(1):22-6. PubMed ID: 7738291 [Abstract] [Full Text] [Related]